NEW YORK, Sept. 6, 2018 /PRNewswire/ -- Bernstein
Liebhard LLP, a nationally acclaimed investor rights law firm,
announces that a new securities class action lawsuit has been filed
on behalf of those who purchased or acquired the securities of
Rockwell Medical, Inc. ("Rockwell" or the "Company") (NASDAQ: RMTI)
between November 8, 2017 and
June 26, 2018, both dates inclusive
(the "Class Period"). The lawsuit, which expands the class period
asserted in the recent lawsuit against the Company concerning
Rockwell's pursuit for separate reimbursement for Triferic, seeks
to recover Rockwell shareholders' investment losses.
To join the Rockwell class action, and/or to discuss your legal
rights and options, please visit Rockwell Medical Shareholder Class
Action Lawsuit or contact Daniel
Sadeh toll free at (877) 779-1414 or
dsadeh@bernlieb.com.
According to the lawsuit, throughout the Class Period
Defendants' made false and/or misleading statements and/or failed
to disclose that: (1) Rockwell was aware that the Centers for
Medicare and Medicaid Services will not pursue Rockwell's proposal
for separate reimbursement for Triferic; (2) the estimated reserves
in Rockwell's Form 10-Q for the quarter ended March 31, 2018 are misstated; (3) there was a
material weakness in Rockwell's internal control over financial
reporting; (4) consequently, Rockwell's internal control over
financial reporting was ineffective during the Class Period; (5)
Robert L. Chioini, former Chief
Executive Officer of Rockwell, withheld material information
regarding Triferic from Rockwell's auditor, corporate counsel and
five independent directors of Rockwell's Board; and (6) as a
result, Defendants' statements about Rockwell's business,
operations and prospects were materially false and misleading
and/or lacked reasonable bases at all relevant times. When the true
details entered the market, the lawsuit claims that investors
suffered damages.
If you wish to serve as lead plaintiff, you must move the Court
no later than September 25, 2018. A
lead plaintiff is a representative party acting on behalf of other
class members in directing the litigation. Your ability to share in
any recovery doesn't require that you serve as lead plaintiff. If
you choose to take no action, you may remain an absent class
member.
To join the Rockwell class action, and/or to discuss your legal
rights and options, please visit
https://www.bernlieb.com/cases/rockwell-medical-inc-rmti-class-action-lawsuit-72/
or contact Daniel Sadeh toll free at
(877) 779-1414 or dsadeh@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over
$3.5 billion for its clients. In
addition to representing individual investors, the Firm has been
retained by some of the largest public and private pension funds in
the country to monitor their assets and pursue litigation on their
behalf. As a result of its success litigating hundreds of lawsuits
and class actions, the Firm has been named to The National Law
Journal's "Plaintiffs' Hot List" thirteen times and listed in
The Legal 500 for ten consecutive years.
ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law
firm responsible for this advertisement is Bernstein Liebhard LLP,
10 East 40th Street, New York, New
York 10016, (212) 779-1414. The lawyer responsible for this
advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
Contact Information
Daniel Sadeh
Bernstein Liebhard LLP
http://www.bernlieb.com
(877) 779-1414
dsadeh@bernlieb.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/september-25th-deadline-alert-bernstein-liebhard-llp-announces-that-a-new-securities-class-action-lawsuit-expanding-the-relevant-class-period-has-been-filed-against-rockwell-medical-inc---rmti-300708482.html
SOURCE Bernstein Liebhard LLP